Literature DB >> 18581185

Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy.

Thomas Yau1, C Y Lo, R J Epstein, A K Y Lam, K Y Wan, Brian H Lang.   

Abstract

BACKGROUND: Anaplastic thyroid carcinoma (ATC) is a notoriously aggressive malignancy associated with a highly lethal clinical course despite therapeutic intervention. Our present study attempts to identify factors that could potentially improve therapeutic strategies by analyzing the clinicopathological features, treatment and outcome of ATC patients managed over the past four decades at our institution.
METHODS: Fifty patients with biopsy-proven ATC during the period 1966 to 2006 were studied. All patients were managed with surgery, radiotherapy, chemotherapy and/or chemoradiation. Survival was calculated by the Kaplan-Meier method. Potential factors affecting survival were compared by the log rank test.
RESULTS: Most patients (88%) presented with a neck mass; 17 patients (34%) also had cervical lymphadenopathy. Distant metastases were clinically present in 9 (18%). Median survival was 97 days, whereas the 1- and 3-year survival was 14% and 8%, respectively. On univariate analysis, patients aged </=65 years (P = .04), absence of metastatic disease at presentation (P < .01), surgical resection (P < .01), and postoperative radiotherapy (P < .01) were associated with longer survival. The adoption of cytotoxic chemotherapy was not associated with better survival (P = .4). Moreover, there was no improvement in survival rate over the last four decades despite the adoption of multimodal treatment (P = .5).
CONCLUSION: ATC remains a deadly disease despite technical advances in surgical technique and adoption of multidisciplinary treatment strategies over the last four decades. However, younger patients with localized ATC might benefit from an aggressive multidisciplinary approach.

Entities:  

Mesh:

Year:  2008        PMID: 18581185     DOI: 10.1245/s10434-008-0005-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  36 in total

Review 1.  Pharmacotherapy options for advanced thyroid cancer: a systematic review.

Authors:  Christian Lerch; Bernd Richter
Journal:  Drugs       Date:  2012-01-01       Impact factor: 9.546

2.  Anaplastic Thyroid Carcinoma, Version 2.2015.

Authors:  Robert I Haddad; William M Lydiatt; Douglas W Ball; Naifa Lamki Busaidy; David Byrd; Glenda Callender; Paxton Dickson; Quan-Yang Duh; Hormoz Ehya; Megan Haymart; Carl Hoh; Jason P Hunt; Andrei Iagaru; Fouad Kandeel; Peter Kopp; Dominick M Lamonica; Judith C McCaffrey; Jeffrey F Moley; Lee Parks; Christopher D Raeburn; John A Ridge; Matthew D Ringel; Randall P Scheri; Jatin P Shah; Robert C Smallridge; Cord Sturgeon; Thomas N Wang; Lori J Wirth; Karin G Hoffmann; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2015-09       Impact factor: 11.908

Review 3.  Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.

Authors:  Eleonora Molinaro; Cristina Romei; Agnese Biagini; Elena Sabini; Laura Agate; Salvatore Mazzeo; Gabriele Materazzi; Stefano Sellari-Franceschini; Alessandro Ribechini; Liborio Torregrossa; Fulvio Basolo; Paolo Vitti; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2017-07-14       Impact factor: 43.330

Review 4.  The "next-generation" knowledge of papillary thyroid carcinoma.

Authors:  Valerio Costa; Roberta Esposito; Pierlorenzo Pallante; Alfredo Ciccodicola; Alfredo Fusco
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

5.  Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options.

Authors:  Francesco Perri; Giuseppe Di Lorenzo; Giuseppina Della Vittoria Scarpati; Carlo Buonerba
Journal:  World J Clin Oncol       Date:  2011-03-10

6.  Survival advantage of chemoradiotherapy in anaplastic thyroid carcinoma: Propensity score matched analysis with multiple subgroups.

Authors:  Sibo Tian; Jeffrey M Switchenko; Teng Fei; Robert H Press; Mustafa Abugideiri; Nabil F Saba; Taofeek K Owonikoko; Amy Y Chen; Jonathan J Beitler; Walter J Curran; Theresa W Gillespie; Kristin A Higgins
Journal:  Head Neck       Date:  2019-12-16       Impact factor: 3.147

7.  Nestin expression as an independent indicator of poor prognosis for patients with anaplastic thyroid cancer.

Authors:  Kento Kurata; Naoyoshi Onoda; Satoru Noda; Shinichiro Kashiwagi; Yuka Asano; Hidemi Kawajiri; Tsutomu Takashima; Sayaka Tanaka; Masahiko Ohsawa; Kosei Hirakawa
Journal:  Oncol Lett       Date:  2015-06-11       Impact factor: 2.967

8.  Influence of risk grouping on therapeutic decisions in patients with anaplastic thyroid carcinoma.

Authors:  Chuanzheng Sun; Chao Li; Zedong Hu; Xiaojiang Li; Jiehua He; Ming Song; Guojun Li; Fenghua Zhang; Qiuli Li
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-10       Impact factor: 2.503

9.  Lenvatinib enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer.

Authors:  Changxin Jing; Zhifei Gao; Rong Wang; Zhao Yang; Bingyin Shi; Peng Hou
Journal:  Am J Cancer Res       Date:  2017-04-01       Impact factor: 6.166

Review 10.  [Surgical therapy for thyroid gland malignancies].

Authors:  P E Goretzki; K Schwarz; B Lammers
Journal:  HNO       Date:  2013-01       Impact factor: 1.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.